An FDA committee endorsed wider use of peptides in lightly regulated compounding pharmacies, which have grown into a multibillion-dollar business. The vote raises concerns about a potential prescribing boom in minimally regulated settings.
An FDA committee voted on July 24, 2026 to recommend making certain peptides available through compounding pharmacies despite FDA staff opposition. Critics noted that some committee members have financial ties to peptide producers, raising conflict-of-interest concerns.